Chris Shibutani
Stock Analyst at Goldman Sachs
(3.59)
# 769
Out of 5,182 analysts
94
Total ratings
56.25%
Success rate
24.94%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $58.73 | +70.27% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $9.90 | -69.70% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $7.09 | +111.57% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $34.14 | -6.27% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $102.06 | +34.23% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $21.11 | +56.32% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $569.11 | -46.93% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $49.54 | +2.95% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $227.79 | -31.95% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $16.31 | -75.48% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $13.32 | +50.15% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $874.00 | -17.28% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $12.24 | +112.42% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $128.12 | +19.42% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $197.69 | -12.49% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $83.81 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $58.26 | +18.43% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $23.69 | -45.12% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $144.83 | -84.12% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $83.85 | -37.98% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $26.48 | +126.59% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $12.89 | +39.64% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $25.14 | -32.38% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.97 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $7.54 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $58.73
Upside: +70.27%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $9.90
Upside: -69.70%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $7.09
Upside: +111.57%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $34.14
Upside: -6.27%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $102.06
Upside: +34.23%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $21.11
Upside: +56.32%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $569.11
Upside: -46.93%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $49.54
Upside: +2.95%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $227.79
Upside: -31.95%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $16.31
Upside: -75.48%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $13.32
Upside: +50.15%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $874.00
Upside: -17.28%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $12.24
Upside: +112.42%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $128.12
Upside: +19.42%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $197.69
Upside: -12.49%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $83.81
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $58.26
Upside: +18.43%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $23.69
Upside: -45.12%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $144.83
Upside: -84.12%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $83.85
Upside: -37.98%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $26.48
Upside: +126.59%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $12.89
Upside: +39.64%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $25.14
Upside: -32.38%
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.97
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $7.54
Upside: -